Trials / Completed
CompletedNCT03734718
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
The Role of Glucose-dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis of Type 1 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Steno Diabetes Center Copenhagen · Academic / Other
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in the daily life of participants with type 1 Diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GIP | Infusion of Glucose-dependent insulinotropic peptide |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2019-12-12
- Completion
- 2019-12-31
- First posted
- 2018-11-08
- Last updated
- 2020-01-27
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03734718. Inclusion in this directory is not an endorsement.